PAUL STEVEN M
PAUL STEVEN M's purchase track record
PAUL STEVEN M has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2025 | RAPP | $1.03M | +27.4% | +17.2% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target. Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Transaction History
| SPTX | ▼ Sell | Other | 67,031 | — | 5/4/2026 | View on chart |
| RAPP | ▲ Buy | Open Market | 28,284 | $693K | 9/12/2025 | View on chart |
| RAPP | ▲ Buy | Open Market | 13,382 | $334K | 9/12/2025 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 15,000 | $170K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 253 | $42K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,235 | $211K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,434 | $247K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 526 | $93K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 825 | $147K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 175 | $31K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 4,948 | $836K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 4,872 | $827K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 642 | $111K | 4/1/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 90 | $16K | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data
Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data. Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.